Showing results (221-230 of 233) with videos related to

Sort By:
Pageof 24
Swiss Medical Weekly|March 2, 2018
Haematopoietic cell transplantation in Switzerland, changes and results over 20 years: a report from the Swiss Blood Stem Cell Transplantation Working Group for Blood and Marrow Transplantation registry 1997-2016Jakob R Passweg, Helen Baldomero, Marc Ansari, et al.
Haematologica|May 20, 2014
Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinibBenjamin Hanfstein, Michael Lauseker, Rüdiger Hehlmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2013
Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IVRüdiger Hehlmann, Martin C Müller, Michael Lauseker, et al.
Blood|November 1, 2011
Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IVAlice Fabarius, Armin Leitner, Andreas Hochhaus, et al.
Leukemia|February 10, 2016
Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IVM B Miranda, M Lauseker, M-P Kraus, et al.
Leukemia|March 27, 2012
Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)B Hanfstein, M C Müller, R Hehlmann, et al.
American Journal of Hematology|October 15, 2013
Improved relapse-free survival after autologous stem cell transplantation does not translate into better quality of life in chronic lymphocytic leukemia: lessons from the randomized European Society for Blood and Marrow Transplantation-Intergroup studyLiesbeth C de Wreede, Maggie Watson, Marleen van Os, et al.
Nature Communications|September 21, 2017
Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axisSara Trabanelli, Mathieu F Chevalier, Amaia Martinez-Usatorre, et al.
Leukemia|October 15, 2015
Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatmentA Gratwohl, M Pfirrmann, A Zander, et al.
Haematologica|December 6, 2018
Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IVChristian Michel, Andreas Burchert, Andreas Hochhaus, et al.
Pageof 24